Document is current

Article History

Received: 2 May 2024

Accepted: 9 September 2024

First Online: 3 October 2024

Declarations

:

: The study was approved by the Committee on Health Research Ethics in the Capital Region of Denmark (protocol number: H-22028111) and by the Danish Data Protection Agency at the Capital Region of Denmark (protocol number: P-2022-354). The study will be conducted in compliance with existing laws on data protection. Any important changes in the protocol will be reported to the Ethics Committee in the Capital Region of Denmark and the Danish Data Protection Agency. Participants will be given written and verbal information about the studies to make an informed decision about their participation. Written informed consent is obtained from all participants using the approved consent form template from the Committee on Health Research Ethics in the Capital Region of Denmark. The participant information materials and informed consent form are available from the corresponding author upon request.

: Not applicable. No identifying images or details of participants are presented here or will be presented in reports of the trial results.

: KWM reports having received consultancy fees from Lundbeck, Angelini, Gideon Richter, and Janssen-Cilag in the past three years. VD, JM, AJ, and CS report no conflicts of interest. LVK reports having received consultancy fees from Lundbeck and Teva in the past three years. In the past three years, GMK has served as a speaker for Angelini, Abbvie, and Compass and as a consultant for Onsero, Sanos, Gilgamesh, Pure Technologies, and Pangea Botanica.